Long-acting Injectable Antipsychotics in First-episode Schizophrenia

키워드

참고문헌 (33)

1. Perkins DO, "Predictors of noncompliance in patients with schizophrenia", J Clin Psychiatry, 63, pp.1121~1128 (2002)
2. Yang J, "Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia", Schizophr Res, 134, pp.226~231 (2012)
3. Glick ID, "The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia", J Clin Psychopharmacol, 31, pp.82~85 (2011)
4. Nasrallah HA, "The case for long-acting antipsychotic agents in the post-CATIE era", Acta Psychiatr Scand, 115, pp.260~267 (2007)
5. Masand PS, "A review of pharmacologic strategies for switching to atypical antipsychotics", Prim Care Companion J Clin Psychiatry, 7, pp.121~129 (2005)
6. Kane JM, "Utilization of long-acting antipsychotic medication in patient care", CNS Spectr, 11(12 Suppl 14), pp.1~7 (2006)
7. Birchwood M, "Early intervention in psychosis. The critical period hypothesis", Br J Psychiatry Suppl, 172, pp.53~59 (1998)
8. Lieberman J, "Time course and biologic correlates of treatment response in first-episode schizophrenia", Arch Gen Psychiatry, 50, pp.369~376 (1993)
9. Lieberman JA, "The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches", Biol Psychiatry, 50, pp.884~897 (2001)
10. Robinson D, "Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder", Arch Gen Psychiatry, 56, pp.241~247 (1999)
11. Carpenter WT Jr, "A comparative trial of pharmacologic strategies in schizophrenia", Am J Psychiatry, 144, pp.1466~1470 (1987)
12. Herz MI, "Intermittent vs maintenance medication in schizophrenia. Two-year results", Arch Gen Psychiatry, 48, pp.333~339 (1991)
13. Gaebel W, "German Study Group on First- Episode Schizophrenia. Relapse prevention in first-episode schizophrenia−maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia", J Clin Psychiatry, 72, pp.205~218 (2011)
14. Jaeger M, "Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists", Psychiatry Res, 175, pp.58~62 (2010)
15. Gerlach J, "Depot neuroleptics in relapse prevention: advantages and disadvantages", Int Clin Psychopharmacol, 9(Suppl 5), pp.17~20 (1995)
16. Taylor DM, "Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients", J Clin Psychiatry, 65, pp.1076~1083 (2004)
17. Geddes J, "Generating evidence to inform policy and practice: the example of the second generation "atypical" antipsychotics", Schizophr Bull, 29, pp.105~114 (2003)
18. Agid O, "Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention", Expert Opin Pharmacother, 11, pp.2301~2317 (2010)
19. Lee MS, "Long-term treatment with long-acting risperidone in Korean patients with schizophrenia", Hum Psychopharmacol, 21, pp.399~407 (2006)
20. Emsley R, "Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies", Clin Ther, 30, pp.2378~2386 (2008)
21. De la Gándara J, "Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study", Expert Rev Neurother, 9, pp.1463~1474 (2009)
22. Shi L, "Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia", Psychiatr Serv, 58, pp.482~488 (2007)
23. Mond J, "Use of antipsychotic medications in Australia between July 1995 and December 2001", Aust N Z J Psychiatry, 37, pp.55~61 (2003)
24. Heres S, "Attitudes of psychiatrists toward antipsychotic depot medication", J Clin Psychiatry, 67, pp.1948~1953 (2006)
25. Tiihonen J, "Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study", BMJ, 333, pp.224~ (2006)
26. Kane JM, "Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia", Arch Gen Psychiatry, 39, pp.70~73 (1982)
27. Emsley R, "Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study", J Clin Psychopharmacol, 28, pp.210~213 (2008)
28. Emsley R, "Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection", Int Clin Psychopharmacol, 23, pp.325~331 (2008)
29. Kim B, "Effectiveness of risperidone long-acting injection in first -episode schizophrenia: in naturalistic setting", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1231~1235 (2008)
30. Weiden PJ, "A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome", J Clin Psychiatry, 70, pp.1397~1406 (2009)
31. Bartzokis G, "Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory", Schizophr Res, 132, pp.35~41 (2011)
32. Masand PS, "Long-acting injectable antipsychotics in the elderly: guidelines for effective use", Drugs Aging, 20, pp.1099~1110 (2003)
33. Masand PS, "Side effects of antipsychotics in the elderly", J Clin Psychiatry, 61(Suppl 8), pp.43~49 (2000)

관련 논문AI추천